When Your Veterinary Practice Sale Falls Through: What to Do Next in 2026
Key takeaways
- Most deals now die in diligence, not at the bank. In a 2025 study of 75 broken letters of intent, diligence findings killed 25.3 percent of deals and earnings discrepancies another 21.3 percent; financing failures fell to 10.7 percent, half their 2023 share.
- The letter of intent protects the buyer more than you. Typically only its exclusivity, confidentiality, and governing-law clauses bind anyone, and the 30 to 45 day exclusivity window is when your leverage bottoms out.
- A retrade is information, not just an insult. More than 90 percent of private-company deals carry price adjustments. A documented, evidence-backed reduction is negotiable; a vague one is a reason to walk.
- The first 30 days decide the second sale. Get the buyer’s exit reason in writing, shut down data access, run an honest postmortem, and steady your team before rumors do it for you.
- A failed sale does not reprice your practice. An unfixed cause does. Fix what diligence found, prove the fix, and re-enter a 2026 market running at more than double the prior year’s deal count.
That phone call finds me a few times every year. An owner, usually 6 or 7 weeks into diligence, tells me the buyer’s team has gone quiet, then that the price has moved, then that the deal is dead.
The tone is always the same. Part grief, part embarrassment, and underneath both, a question the owner is almost afraid to ask out loud: is my practice damaged goods now?
It isn’t. But what you do in the next 30 days determines whether the second run at the market goes better than the first, and most owners get those 30 days wrong.
If your veterinary practice sale fell through, work the sequence in order. Get the buyer’s reason for walking in writing, lock down your financial data, and tell your team something true before rumors reach them.
Then fix the specific problem that killed the deal. Only after that do you go back to market, with the fix documented.
Speed matters less than proof.
Why do veterinary practice sales fall through in 2026?
Deals in 2026 die in due diligence far more often than they die at the bank.
Across 75 broken LOIs analyzed in a 2025 dead-deal study, non-financial diligence findings caused 25.3 percent of failures and earnings discrepancies 21.3 percent, while financing failures fell to 10.7 percent, half their 2023 rate.
That shift matters, because most owners still prepare for the wrong risk. A decade of stories about buyers losing their loans taught sellers to vet the buyer’s money.
Good instinct. Wrong decade.
Axial’s January 2026 dead-deal analysis found that quality of earnings problems, the deep financial review the buyer’s accountants run to test whether your reported EBITDA holds up, killed 21.3 percent of broken LOIs in 2025, more than double 2023’s 10.6 percent.
And the misses aren’t rounding errors: one respondent reported EBITDA landing between $265,000 and $594,000 lower after the accountants finished, which on a typical multiple is 7 figures of price evaporating mid-deal.
Here is the full cause breakdown, with the direction of travel since 2023:
| Why the deal died | Share of broken LOIs, 2025 | Trend vs. 2023 |
|---|---|---|
| Diligence findings (non-financial) | 25.3 percent | Leading cause |
| Quality of earnings / EBITDA discrepancies | 21.3 percent | Doubled from 10.6 percent |
| Failed renegotiations (retrades that collapsed) | 14.7 percent | Persistent |
| Seller decisions (seller walked or froze) | 13.3 percent | Persistent |
| Financing failure | 10.7 percent | Halved from 21.3 percent |
| Underperformance during the deal | 8.0 percent | Smaller but real |
Two vet-specific layers sit on top of that general pattern. Legal and compliance gaps, think incomplete DEA logs, unresolved OSHA items, sloppy associate agreements, kill and discount veterinary deals specifically; healthcare M&A counsel notes that buyers cut their offers hard when they find legal uncertainty.
And in a few states, deals can now die on regulatory review before diligence even matters. New York’s proposed A9042 would give the state 14 days’ notice and the attorney general blocking power over veterinary transactions of $200,000 or more.
Notice what mostly isn’t on the list: the practice itself. In my experience the medicine is almost never the problem.
The paperwork about the medicine is.
Is the letter of intent binding, and can the buyer just walk?
In most deals, yes, the buyer can walk. An LOI, the short pre-diligence agreement setting headline price and structure, is typically non-binding except for its exclusivity, confidentiality, and governing-law provisions.
The buyer who terminates during diligence usually owes you nothing beyond keeping your information confidential.
This is the part that shocks owners most, so let me say it plainly. That number you celebrated over dinner when the LOI came in?
It was never a promise.
M&A counsel at Mintz put the seller’s position bluntly in a 2025 analysis: once you sign, your only real leverage is that the buyer might lose the deal.
During the exclusivity window, typically 30 to 45 days, you can’t talk to other buyers while this one decides whether to keep its word on price.
The asymmetry is reliable enough to treat as law: the seller’s protection is never inside the LOI.
It’s upstream, in how many qualified buyers were at the table before anyone signed, and owners who took the first respectable offer, a path I walk through in the top mistakes owners make selling a veterinary practice, had no fallback the day the buyer blinked.
Should you accept a lower price after diligence, or walk away?
Judge the retrade by its evidence, not its existence. A price reduction tied to a specific, documented finding, like a verified earnings adjustment, is a negotiation.
A vague haircut with no supporting work is a preview of how this buyer behaves at every future decision point, and walking is often the right answer.
A retrade, when the buyer comes back after diligence asking for less than the LOI number, feels like betrayal. Sometimes it is.
But hold two facts at once before you react.
First: price movement between signing and closing is normal deal mechanics, not scandal.
SRS Acquiom’s 2025 study of more than 1,200 private-company deals found working capital purchase price adjustments, the true-up for inventory, receivables, and payables actually on hand at closing, in more than 90 percent of transactions, up from roughly half a decade ago.
Second: retrades that collapse deals killed 14.7 percent of 2025’s broken LOIs. The negotiation itself is a danger zone.
The test I use is simple. Show me the work.
If the accountants found that a chunk of your revenue came from a service line you’re winding down, and they can document it, that retrade is information. Accepting a documented, fair reduction sometimes beats 6 more months of market time.
If the buyer’s team can’t or won’t show the work? Different animal entirely.
An unexplained reduction late in exclusivity, timed for when they believe you’re too tired to walk, tells you what 5 years of earnout disputes with this buyer would feel like.
Axial’s report framed the modern deal well, calling a signed LOI “a checkpoint” rather than a finish line. Treat the retrade conversation as the checkpoint where you find out who you’re actually dealing with.
What should you do in the first 30 days after your sale falls through?
Six moves, in order. Get the termination reason in writing, shut down all data access, and run an honest postmortem on which of 4 causes killed the deal.
Then steady your team with a short true statement, fix the documented cause, and set relist timing based on proof rather than emotion.
Get the reason in writing. Some buyers will dodge; most will give you something. You can’t fix an undiagnosed problem, and when the next buyer asks what happened, a documented fact beats your best guess.
Close the data room. Revoke every document permission the same week, and confirm in writing that confidentiality survives termination. Your financials and staff compensation are now sitting in the files of a group that may bid against your interests next year.
Run the postmortem honestly. Every dead deal I’ve dissected sorts into 1 of 4 buckets: a diligence finding, a financing failure, a retrade you refused, or cold feet, theirs or yours. Misdiagnosing the bucket is how owners relist into a second failure.
Cold feet cuts both ways. Seller decisions killed 13.3 percent of 2025’s broken deals, and I’ve sat with owners who quietly torpedoed their own closings because they weren’t ready to stop being the person the whole town brings their dog to.
If that’s the honest diagnosis, deciding when to sell your veterinary practice is the conversation to have before round 2, not after it.
Steady the team. Covered below, because it’s the piece owners fumble most.
Fix, then prove. Covered below as well.
Set timing on evidence. Not on embarrassment, and not on fear that the window is closing. It isn’t.
What do you tell your staff when the deal dies?
Tell key people something short, true, and calm: you explored a transaction, it did not meet your standards, and nothing changes day to day. Never deny what staff already know, and never over-explain.
Associates judge whether you seem in control, and DVM recruiters are calling them regardless.
Confidentiality after a busted deal is damage control, not damage prevention. If diligence got far enough to kill the deal, people noticed things.
The bookkeeper pulled unusual reports; someone saw visitors in street clothes touring the treatment area on a Tuesday.
The rumor mill will process those observations with or without you. Your only choice is whether it processes them alongside your version or in place of it.
The script that works is 2 sentences long. “We looked seriously at a partnership opportunity, and it didn’t meet the standard I’d need to say yes. Nothing about your job, your pay, or how we practice changes.”
Notice what that framing does. You evaluated them.
Not the reverse.
Your associates deserve extra attention here, and not only because replacing a DVM is brutal in this market.
An associate who hears “the practice almost sold” from a recruiter before hearing anything from you has just learned their future gets decided without them in the room, and that, not the sale itself, is what starts the quiet job search.
Clients are simpler. In the general-practice deals I see, clients almost never learn a sale was contemplated unless staff tell them, so the client-facing answer is to give your staff nothing anxious to repeat.
Will buyers think your practice is shopworn in 2026?
Serious buyers care why the deal died, not that it died. In a market this concentrated, assume they’ll hear something; your job is making sure the first version they hear is your documented, one-line account with proof the issue is fixed.
The 2026 market itself is more forgiving, with deal activity running well above 2025.
Owners fear the scarlet letter: that practice that didn’t close. The fear is understandable and mostly wrong, for 3 reasons.
First, the buyer pool knows the base rates.
The groups acquiring at scale have watched their own deals die in diligence too.
PE-backed groups are private equity firms that build networks of practices. With other consolidators they already own roughly 25 percent of primary-care practices, representing about half of nationwide veterinary revenue, per peer-reviewed 2025 research.
These are professional acquirers. A busted prior deal reads as Tuesday, not tragedy.
Second, the market you’re re-entering is healthier than the one your deal died in. Capstone Partners counted 18 announced or completed pet-sector transactions in early 2026 against 8 in the prior-year period, with veterinary and health deals leading at 9.
Buyers are transacting again, and what private equity is paying for veterinary practices remains a competitive question when several of them want the same practice.
Third, and least understood: not every buyer is equally likely to close, and a failed deal is your excuse to get choosier.
Credit research from Octus shows real balance-sheet strain among some large PE-backed veterinary groups, with lenders holding $3.1 billion in veterinary loans as of late 2025 and marking some of those loans as low as 88 cents on the dollar.
One large group ran a distressed debt exchange in March 2025.
I don’t read that as an indictment of any buyer, and stress varies enormously group by group. I read it as a diligence checklist that runs in reverse.
This time, you vet their ability to close with the same rigor they’ll vet your EBITDA, meaning what your practice earns in pure operating profit before taxes and accounting choices.
This is also where process design does the confidentiality work for you.
When we run the Elite Selling System, we hand-select and vet every buyer who gets to bid on your practice, the way a doorman with a velvet rope lets in only the right people.
The story of any prior process then gets told once, accurately, inside a controlled bidding group, instead of leaking sideways through a market that loves gossip.
The shopworn practice isn’t the one that had a deal die. It’s the one that relisted 3 times with the same unfixed problem, because that pattern every buyer recognizes.
What should you fix before going back to market?
Fix whatever the postmortem found, in this priority order: financial records that will survive the next accounting review, legal and compliance gaps like licensing and DEA documentation, tax and allocation positions agreed upfront, and a realistic view of buyer financing under 2025’s tighter SBA rules.
Then document each fix so it’s provable.
Start with the numbers, because that’s where 2 of the top 3 deal-killers live.
When we prepare a practice for sale, part of the work is a thorough pre-sale financial review on our side of the table, built around exactly the kind of scrutiny the buyers’ accountants will run, but before any of those buyers see your numbers.
That sequencing, review first, market second, is most of what separates a first process from a failed one, and it’s the discipline running through our full guide to selling a veterinary practice.
Legal cleanup comes second. The healthcare law firms that work these deals point to the same recurring killers: incomplete corporate records, unsigned or expired associate agreements, unresolved DEA, OSHA, or IRS items.
None of these is hard to fix in a quiet month; all of them are expensive to discover in week 6 of exclusivity.
Tax mechanics deserve an hour with your CPA before, not during, the next process.
In an asset sale, both sides must file IRS Form 8594 allocating the purchase price across 7 asset classes, and allocation fights are a classic late-stage friction point because the split drives how much of your proceeds get taxed as capital gain versus ordinary income.
Agree on the allocation framework in the LOI next time.
And if your likely buyer is an individual or an associate rather than a PE-backed group, respect what happened to financing rules in mid-2025.
The SBA’s new standard operating procedure, effective June 1, 2025, requires a minimum 10 percent equity injection on ownership changes.
A seller note counts toward that injection only if it sits on full standby for the entire loan term and covers no more than half the injection.
Partial ownership changes are also forced into stock-purchase structures, with personal guarantees from all equity holders for at least 2 years.
The 7(a) program still caps at $5 million. An individual buyer who penciled out in 2024 may simply not pencil anymore, and knowing that before you grant exclusivity is worth real money.
Does a failed sale lower what your practice is worth?
No. Buyers price earnings quality, staff stability, client base, and growth, and none of those changed the day your deal died.
What lowers value is relisting with the same unfixed problem, because the next accounting review will find what the last one found. Value the fundamentals, then fix what diligence flagged.
Be honest with yourself about the demand backdrop, because your next buyer will underwrite against it.
Visits across the profession fell roughly 3 percent in 2025 while revenue grew only about 2.5 percent, and the share of veterinarians reporting rising client cost sensitivity climbed from 72 percent to 81 percent, per AVMA-reported survey data.
Vetsource’s tracking panel of more than 6,400 practices, averaging $2.2 million in revenue, shows the same shape: revenue up 2.2 percent, visits down 2.9 percent year over year.
Read that correctly. It’s not a reason to discount your practice; it’s the reason a well-run $2 million-plus practice with defensible earnings stands out, because buyers re-underwriting a soft-traffic market pay up for the practices that grew anyway.
The supply side tells the same story from the other direction. Peer-reviewed survey work finds 61 percent of veterinarians plan to reduce clinical work within 5 years and 31 percent plan to stop entirely.
More practices will come to market over this decade, which means buyers can be patient, which means the practices that command premiums are the prepared ones.
A failed first process, honestly fixed, can leave you more prepared than owners who’ve never been through diligence at all.
If you’re unsure where your practice actually sits after all this, start with a clear-eyed valuation of your veterinary practice using post-postmortem numbers, not the ones from the dead deal’s LOI.
What to do next
A busted deal hands you two things most sellers never get: a free map of exactly what buyers will scrutinize, and a second chance to run the process the way it should have run the first time.
The owners who come out ahead are the ones who use both.
If your deal just died, or you can feel one wobbling, this is the moment to get an outside read before you make the next move.
We’ve walked owners through the morning after enough times to know which causes are cosmetic, which ones are structural, and which buyers at your table were never going to close.
A free, confidential practice value estimate is the lowest-commitment way to get that number.
The estimate gives you a current, defensible read on what your practice should command in this market, and where your numbers stand against what buyers’ accountants will test.
It also shows what a structured competitive process would change about your position, whether your last process ended last month or never started.
And because our engagement is success-based, with fees that vary depending on the value of the practice, we only do well when your sale actually closes, at a number worth closing on. Nobody on our side gets paid for a deal that falls apart.
Frequently asked questions
Can a buyer back out after signing a letter of intent?
Yes, in almost every case. An LOI is mostly non-binding on price and terms; typically only the exclusivity, confidentiality, and governing-law provisions bind either side.
A buyer who walks during diligence usually owes you nothing, which is why the diligence-ready condition of your practice matters so much before you sign.
How common is it for a veterinary practice sale to fall through?
No one publishes a clean vet-specific failure rate, and the widely repeated figures trace to unreliable sources. What is well documented is the cause pattern: across 75 broken LOIs analyzed in a 2025 dead-deal study, diligence findings were the leading killer, followed by earnings discrepancies, failed renegotiations, seller decisions, and financing.
Should I accept the buyer’s lower price after due diligence?
It depends entirely on whether the reduction is documented. A retrade tied to a specific, verifiable finding, like an earnings adjustment the accountants can show you, is a data point worth negotiating.
A vague reduction with no supporting work is a signal about how this buyer will behave at every future decision point, and walking is often right.
How soon can I go back to market after a failed sale?
As soon as the cause of the failure is fixed and provable, which for financial cleanups often means 2 to 6 months. Going back sooner with the same unfixed problem invites the same result, and a second busted deal is far more damaging than a deliberate pause.
Will other buyers find out my deal fell through?
In a market this concentrated, assume the serious buyers will hear something. You cannot prevent that; you can control what the next buyer hears first.
A one-line, factual account of why the deal ended, delivered proactively with evidence the issue is fixed, beats letting them fill the silence with speculation.
What do I tell staff who heard the practice was for sale?
Something short, true, and calm: you explored a transaction, it did not meet your standards, and nothing changes day to day. Do not deny what they already know, and do not over-explain.
Your associates are watching whether you seem in control of the process, because recruiters are calling them either way.
Does a failed sale lower my practice’s value?
The failure itself does not reprice the practice; buyers pay for earnings, staff stability, and growth, none of which changed the day the deal died. What lowers value is relisting with the same unfixed diligence problem, because the next buyer’s accountants will find exactly what the last ones found.
Does the buyer have to pay me anything if they walk away?
Usually not. Breakup fees are uncommon in practice-scale transactions, and most LOIs let either side exit diligence without penalty.
Your real protection is upstream: a competitive process with multiple qualified bidders, tight exclusivity windows of 30 to 45 days, and a practice whose numbers survive scrutiny.
Sources
Industry M&A research and deal data
- Axial. “Dead Deal Report: Unpacking 2025’s Broken LOIs.” January 27, 2026. axial.net
- SRS Acquiom. “2025 Working Capital Purchase Price Adjustment Study.” 2025. srsacquiom.com
- SRS Acquiom. “2025 M&A Deal Terms Study.” 2025. srsacquiom.com
- Capstone Partners. “Pet Sector M&A Update.” April 10, 2026. capstonepartners.com
- Octus. “Private-Credit Exposure to Veterinary Rollups Shows Growing Dispersion; VSOs Under Increasing Pressure.” January 16, 2026. octus.com
Legal and regulatory analysis
- Mintz. “Seller Considerations When Negotiating a Letter of Intent.” March 31, 2025. mintz.com
- Whiteford, Taylor & Preston. “Client Alert: SBA Issues SOP 50 10 8 — Key Changes Impacting SBA 7(a) Lending.” 2025. whitefordlaw.com
- Dental & Medical Counsel. “The Complete Legal Checklist for Selling a Veterinary Practice.” October 8, 2025. dmcounsel.com
- Mintz. “No ‘Paws’ in Oversight: Will New York’s Proposed Veterinary Transaction Review Law Take Effect in 2026?” January 14, 2026. mintz.com
Deal financing and tax (government primary sources)
- U.S. Small Business Administration. “7(a) Loans.” Current official program page. sba.gov
- Internal Revenue Service. “About Form 8594, Asset Acquisition Statement Under Section 1060.” Reviewed March 30, 2026. irs.gov
Veterinary practice operations, benchmarks, and profession data
- AVMA News. “Veterinarians report increasing price sensitivity, decreasing visits.” February 13, 2026. avma.org
- Vetsource Veterinary Analytics. “Veterinary Industry Summary, Week of October 12–18, 2025.” October 21, 2025. veterinaryanalytics.com
- Frontiers in Veterinary Science. “Making the case for a resurgent U.S. independent veterinary practice segment: a SWOT analysis.” May 13, 2025. frontiersin.org
- Frontiers in Veterinary Science. “Career transition plans of veterinarians in clinical practice.” July 26, 2024. pmc.ncbi.nlm.nih.gov
Melani Seymour, co-founder of Transitions Elite, helps veterinary practice owners take action now to maximize value and secure their future.
With over 15 years of experience guiding thousands of owners, she knows exactly what it takes to achieve the best outcome.
